On September 23, 2026, Anthropic reported that Claude helped identify an enzyme system called array-associated reverse transcriptases (ART). This is an early research finding, not an established medical treatment.
What Claude identified
According to Anthropic, Claude spotted DNA repeats and an accessory protein near a previously identified reverse transcriptase in bacteriophages—viruses that infect bacteria. The repeat arrangement resembles CRISPR, but that resemblance does not establish that ART works like CRISPR.
What remains unknown
Anthropic says ART’s function is still unknown. Human scientists performed laboratory experiments, and further investigation is underway. The announcement does not establish clinical trials, approved therapies, commercial products, or demonstrated uses in biofuels and pollution cleanup.
How to interpret the announcement
It illustrates AI-assisted analysis producing a candidate for scientific investigation. Finding an unusual biological pattern and proving a useful application are different milestones.
Correction: An earlier version included an unsupported 2023–2024 timeline and application claims. Those statements and unrelated references have been removed.
Source
Anthropic’s original announcement and linked technical report.
